Sally Crawford

Sally Crawford sits as a director at four US companies: Hologic Inc (40 filings), Insulet Corp (15), Universal American Corp. (4) and ZimVie Inc. (2). That makes 61 filings published from January 5, 2016 to October 20, 2025.

Option exercises (27) outnumber sales (15), and there are also 16 grants and 2 filings of another kind. The sales total EUR 12,857,737, with a median of EUR 679,884. The largest took place at Insulet, EUR 2,765,649 on May 31, 2019 and EUR 2,217,711 on June 4, 2021, then at Hologic, EUR 1,516,566 on May 22, 2020. The record holds a single purchase, EUR 209,779 at ZimVie on March 13, 2023, which is 6% of market trades.

The year 2017 is the busiest, with 19 filings, ahead of 2019 (12) and 2016 (10). Since 2022 there have been 1 or 3 a year. None falls in the last twelve months. Filings appear a median of 2 days after the trade.

Crawford has 6, 4 and 4 own market trades within 30 days of colleagues at Hologic Inc, in that order. All on the same side. The colleagues, in the same order: Elaine Ullian, Lawrence M. Levy and Peter J. Valenti III.